Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study
Open Access
- 1 January 2022
- journal article
- research article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (2) , 93
Abstract
Background: The discordance of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 cell nuclear proliferation antigen status in patients with locally advanced breast cancer pre- and post-neoadjuvant chemotherapy (NAC) is quite common. This study aimed to assess the frequency of changes in receptor status after NAC in patients with invasive ductal breast cancer and the prognostic impact of such changes. Methods: The study comprised 670 patients who were diagnosed with invasive ductal breast carcinoma and treated with both NAC and surgery from 2012–2017. Hormone receptor (HR; including ER and PR), HER2, and Ki-67 status was assessed before NAC and in residual invasive tumor cells of the surgical specimens. The prognostic impact of receptor conversions in breast cancer patients treated with NAC was evaluated in this retrospective study. Results: The conversion of ER was related to overall survival (OS; P=0.008) and disease-free survival (DFS; P=0.004). Patients whose ER status was always positive had the best prognosis, and those who were always negative had the worst prognosis. Similar results were also found for PR status, as the conversion of PR status was also related to OS (PConclusions: Changes in receptor status between pre-treatment and residual disease after NAC are common. Moreover, these alterations have an impact on the survival outcome of invasive ductal breast cancer patients. Thus, receptor status should be re-evaluated routinely before and after NAC to guide individualized treatment.Keywords
This publication has 25 references indexed in Scilit:
- Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival OutcomesClinical Breast Cancer, 2015
- Evaluation of hormone receptor, human epidermal growth factor receptor‐2 and Ki‐67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patientsThoracic Cancer, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Breast cancer intra-tumor heterogeneityBreast Cancer Research, 2014
- Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patientsAnnals of Oncology, 2013
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancerCancer Treatment Reviews, 2010
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBritish Journal of Cancer, 2009
- Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other FactorsJournal of Clinical Oncology, 2006